Metastatic Triple Negative Breast Cancer
Conditions
Brief summary
This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.
Detailed description
The primary aims of the study are: * To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer (TNBC) patients by determining the objective response rate (ORR), using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as assessed by the Investigator. * To characterize the safety profile of tumor infiltrating lymphocytes (TIL) as a single therapy in Metastatic Triple Negative Breast Cancer patients as measured by the incidence of Grade ≥ 3 treatment-emergent adverse events (TEAEs). The secondary aims of the study are: • To further evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer patients using complete response duration of response (DOR), disease control rate (DCR), and progression-free survival (PFS), using RECIST 1.1, as assessed by the Investigator, overall survival (OS) and (CR) rate.
Interventions
DRUGTumor infiltrating lymphocytes (TIL) LN-145
The TIL autologous therapy with LN-145 is comprised of the following steps: 1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product; 2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility; 3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards); 4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization); 5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization).
Sponsors
Iovance Biotherapeutics, Inc.
Yale University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to understand the requirements of the study. Specifically, the patient has to provide written informed consent (as evidenced by signature on an ICF approved by the Yale Human Investigation Committee (HIC). * All patients must have a triple negative metastatic breast cancer (Estrogen Receptor negative, Progesterone Receptor negative, HER2 negative) as defined by the 2018 ASCO CAP guidelines. * Patients must have a confirmed diagnosis of metastatic triple negative breast cancer (Stage IV) histologically confirmed as per American Joint Committee on Cancer \[AJCC\] staging system). * Patients must have had at least one and no more than three prior lines of systemic anticancer therapies for metastatic disease. * Patients must have disease progression from the last line of therapy. * Patients must have at least one resectable lesion of a minimum 1.5 cm in diameter (or aggregate of 1.5 cm if multiple lesions are sampled) post-resection for TIL investigational product production. * Patients must have remaining measurable disease as defined by RECIST 1.1 following tumor resection for TIL manufacturing * Patients must be ≥ 18 years of age at the time of consent. * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and an estimated life expectancy of ≥ 3 months in the opinion of the Investigator. * Female patients of childbearing potential or female partners of childbearing potential of male participants, must be willing to practice an approved method of birth control during treatment and for 12 months after receiving all protocol-related therapy. * Patients must have the following hematologic parameters: * Absolute neutrophil count (ANC) ≥ 1000/mm3; * Hemoglobin ≥ 9.0 g/dL; * Platelet count ≥ 100,000/mm3 * Patients must have adequate organ function. * Patients must be seronegative for the human immunodeficiency virus (HIV1 and HIV2). * Patients must have a washout period of 21 days from last anticancer therapy prior to the first study treatment (ie, start of NMA LD). * Palliative radiation therapy: prior external beam radiation is allowed provided all radiation-related toxicities are resolved to Grade 1 or baseline; * The tumor lesion(s) being assessed as target for response via RECIST 1.1 must be outside of the radiation portal (however, if within the portal, they must have demonstrated progression); * Surgery/pre-planned procedure: previous surgical procedure(s) is permitted provided that wound healing has occurred, all complications have resolved, and at least 14 days have elapsed (for major operative procedures) prior to the tumor resection. * Patients must have recovered from all prior anticancer treatment-related adverse events (TRAEs) to Grade ≤ 1 (per Common Terminology Criteria for Adverse Events \[CTCAE\], version 5.0). * Patients must have provided written authorization for use and disclosure of protected health information. * Must be able and willing to comply with the study visit schedule and protocol requirements including long-term follow-up (LTFU).
Exclusion criteria
* Patients who have received an organ allograft or prior cell transfer therapy within the past 20 years that included a nonmyeloablative or myeloablative chemotherapy regimen. * Patients with symptomatic and/or untreated brain metastases: * Patients who are on systemic steroid therapy except for those requiring steroid for management of adrenal insufficiency. * Patients who are pregnant or breastfeeding. * Patients who have active medical illness(es) that would pose increased risk for study participation * Patients who have received a live or attenuated vaccination within 28 days prior to the start of NMA-LD. * Patients who have any form of primary immunodeficiency (such as severe combined immunodeficiency disease \[SCID\] and acquired immune deficiency syndrome \[AIDS\]). * Patients with a history of hypersensitivity to any component of the study drugs. * Patients who have a left ventricular ejection fraction (LVEF) \< 45% or who are New York Heart Association (NYHA) Class II or higher. * Patients who have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) ≤ 60% of predicted normal. * Patients who have had another primary malignancy within the previous 3 years (except for curatively treated localized malignancy that has not required treatment for greater than 1 year. * Participation in another clinical study with an investigational product within 21 days of the initiation of NMA-LD treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to 4 months | To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer (TNBC) patients by determining the objective response rate (ORR), using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as assessed by the Investigator. Upon results entry, the time frame was updated to reflect the latest time point that a participant was assessed for ORR in the study. |
| Safety Profile | Up to 3 years | To characterize the safety profile of tumor infiltrating lymphocytes (TIL) as a single therapy in Metastatic Triple Negative Breast Cancer patients as measured by the incidence of Grade ≥ 3 treatment-emergent adverse events (TEAEs). Incidence is presented as a count of participants that experienced at least 1 TEAE of Grade ≥ 3. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Up to 3 years | To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer patients, median progression-free survival (PFS) days, using RECIST 1.1, as assessed by the Investigator will be used. |
| Duration of Response (DOR) in Days | Up to 3 years | To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer patients in participants that have a clinical response (either partial response (PR) or complete response (CR)) using duration of response (DOR), using RECIST 1.1, as assessed by the Investigator will be used. |
| Complete Response (CR) | Up to 3 years | To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast patients complete response, using RECIST 1.1, as assessed by the Investigator will be used. The number of participants with a complete response. |
| Overall Survival (OS) | Up to 3 years | To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast patients overall survival (OS) median days will be used. |
| Disease Control Rate (DCR) | Up to 3 years | To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer patients using disease control rate (DCR), using RECIST 1.1, as assessed by the Investigator will be used. Percentage of patients whose disease shrinks or remains stable over a certain time period. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| LN-145 LN-145 will be delivered as a single therapy in patients with Metastatic Triple Negative Breast Cancer.
Tumor infiltrating lymphocytes (TIL) LN-145: The TIL autologous therapy with LN-145 is comprised of the following steps:
1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;
2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;
3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);
4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);
5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization). | 6 |
| Total | 6 |
Baseline characteristics
| Characteristic | LN-145 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 6 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 5 Participants |
| Region of Enrollment United States | 6 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 6 / 6 |
| other Total, other adverse events | 6 / 6 |
| serious Total, serious adverse events | 4 / 6 |
Outcome results
Primary
Objective Response Rate (ORR)
To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer (TNBC) patients by determining the objective response rate (ORR), using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as assessed by the Investigator. Upon results entry, the time frame was updated to reflect the latest time point that a participant was assessed for ORR in the study.
Time frame: Up to 4 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LN-145 | Objective Response Rate (ORR) | complete response (CR) | 0 Participants |
| LN-145 | Objective Response Rate (ORR) | partial response (PR) | 1 Participants |
| LN-145 | Objective Response Rate (ORR) | stable disease (SD) | 1 Participants |
| LN-145 | Objective Response Rate (ORR) | progressive disease (PD) | 4 Participants |
Primary
Safety Profile
To characterize the safety profile of tumor infiltrating lymphocytes (TIL) as a single therapy in Metastatic Triple Negative Breast Cancer patients as measured by the incidence of Grade ≥ 3 treatment-emergent adverse events (TEAEs). Incidence is presented as a count of participants that experienced at least 1 TEAE of Grade ≥ 3.
Time frame: Up to 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LN-145 | Safety Profile | 3 Participants |
Secondary
Complete Response (CR)
To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast patients complete response, using RECIST 1.1, as assessed by the Investigator will be used. The number of participants with a complete response.
Time frame: Up to 3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LN-145 | Complete Response (CR) | 0 Participants |
Secondary
Disease Control Rate (DCR)
To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer patients using disease control rate (DCR), using RECIST 1.1, as assessed by the Investigator will be used. Percentage of patients whose disease shrinks or remains stable over a certain time period.
Time frame: Up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| LN-145 | Disease Control Rate (DCR) | 66.6 percentage of participants |
Secondary
Duration of Response (DOR) in Days
To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer patients in participants that have a clinical response (either partial response (PR) or complete response (CR)) using duration of response (DOR), using RECIST 1.1, as assessed by the Investigator will be used.
Time frame: Up to 3 years
Population: Only assessed in participants that had a PR. Only one participant had a PR. Method of dispersion was not collected as was only one participant.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| LN-145 | Duration of Response (DOR) in Days | 79 days |
Secondary
Overall Survival (OS)
To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast patients overall survival (OS) median days will be used.
Time frame: Up to 3 years
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| LN-145 | Overall Survival (OS) | 156.5 days | Standard Deviation 66.8 |
Secondary
Progression-free Survival (PFS)
To evaluate the efficacy of autologous LN-145 as a single therapy in Metastatic Triple Negative Breast Cancer patients, median progression-free survival (PFS) days, using RECIST 1.1, as assessed by the Investigator will be used.
Time frame: Up to 3 years
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| LN-145 | Progression-free Survival (PFS) | 46.5 days | Standard Deviation 19.8 |